475 related articles for article (PubMed ID: 9420201)
1. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
3. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
5. Variability of herpes simplex virus 1 gL and anti-gL antibodies that inhibit cell fusion but not viral infectivity.
Novotny MJ; Parish ML; Spear PG
Virology; 1996 Jul; 221(1):1-13. PubMed ID: 8661409
[TBL] [Abstract][Full Text] [Related]
6. Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex.
Peng T; Ponce de Leon M; Novotny MJ; Jiang H; Lambris JD; Dubin G; Spear PG; Cohen GH; Eisenberg RJ
J Virol; 1998 Jul; 72(7):6092-103. PubMed ID: 9621073
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM.
Nicola AV; Ponce de Leon M; Xu R; Hou W; Whitbeck JC; Krummenacher C; Montgomery RI; Spear PG; Eisenberg RJ; Cohen GH
J Virol; 1998 May; 72(5):3595-601. PubMed ID: 9557640
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge.
Ghiasi H; Cai S; Slanina S; Nesburn AB; Wechsler SL
Antiviral Res; 1995 Oct; 28(2):147-57. PubMed ID: 8585768
[TBL] [Abstract][Full Text] [Related]
10. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.
Awasthi S; Lubinski JM; Friedman HM
Vaccine; 2009 Nov; 27(49):6845-53. PubMed ID: 19761834
[TBL] [Abstract][Full Text] [Related]
11. Analysis of protective immune responses to the glycoprotein H-glycoprotein L complex of herpes simplex virus type 1.
Browne H; Baxter V; Minson T
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2813-7. PubMed ID: 8277292
[TBL] [Abstract][Full Text] [Related]
12. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ
J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729
[TBL] [Abstract][Full Text] [Related]
13. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
15. Localization of the Interaction Site of Herpes Simplex Virus Glycoprotein D (gD) on the Membrane Fusion Regulator, gH/gL.
Cairns TM; Atanasiu D; Saw WT; Lou H; Whitbeck JC; Ditto NT; Bruun B; Browne H; Bennett L; Wu C; Krummenacher C; Brooks BD; Eisenberg RJ; Cohen GH
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759318
[TBL] [Abstract][Full Text] [Related]
16. Regulation of herpes simplex virus gB-induced cell-cell fusion by mutant forms of gH/gL in the absence of gD and cellular receptors.
Atanasiu D; Cairns TM; Whitbeck JC; Saw WT; Rao S; Eisenberg RJ; Cohen GH
mBio; 2013 Feb; 4(2):. PubMed ID: 23443004
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Vesicular Stomatitis Virus Pseudotypes Bearing Essential Entry Glycoproteins gB, gD, gH, and gL of Herpes Simplex Virus 1.
Rogalin HB; Heldwein EE
J Virol; 2016 Nov; 90(22):10321-10328. PubMed ID: 27605677
[TBL] [Abstract][Full Text] [Related]
18. Structure-function analysis of herpes simplex virus type 1 gD and gH-gL: clues from gDgH chimeras.
Cairns TM; Milne RS; Ponce-de-Leon M; Tobin DK; Cohen GH; Eisenberg RJ
J Virol; 2003 Jun; 77(12):6731-42. PubMed ID: 12767993
[TBL] [Abstract][Full Text] [Related]
19. Using Antibodies and Mutants To Localize the Presumptive gH/gL Binding Site on Herpes Simplex Virus gD.
Atanasiu D; Saw WT; Lazear E; Whitbeck JC; Cairns TM; Lou H; Eisenberg RJ; Cohen GH
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282715
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
